Corvus Pharmaceuticals, Inc. Stock price

Equities

CRVS

US2210151005

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.78 USD -0.56% Intraday chart for Corvus Pharmaceuticals, Inc. -3.78% +1.14%
Sales 2024 * - Sales 2025 * - Capitalization 87.29M
Net income 2024 * -33M Net income 2025 * -45M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-3.12 x
P/E ratio 2025 *
-2.83 x
Employees 28
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.43%
More Fundamentals * Assessed data
Dynamic Chart
Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating MT
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2 MT
Transcript : Corvus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday MT
Corvus Pharmaceuticals Says Soquelitinib Received FDA Orphan Drug Designation MT
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation DJ
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer CI
Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors CI
Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial CI
Transcript : Corvus Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
More news
1 day-0.56%
1 week-3.78%
Current month-20.54%
1 month-24.58%
3 months+3.49%
6 months+22.76%
Current year+1.14%
More quotes
1 week
1.71
Extreme 1.71
1.88
1 month
1.71
Extreme 1.71
2.39
Current year
1.65
Extreme 1.65
2.58
1 year
0.66
Extreme 0.66
4.19
3 years
0.61
Extreme 0.607
9.54
5 years
0.61
Extreme 0.607
9.54
10 years
0.61
Extreme 0.607
22.14
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 14-01-26
Director of Finance/CFO 70 14-01-26
Chief Tech/Sci/R&D Officer - 22-07-20
Members of the board TitleAgeSince
Chief Executive Officer 73 14-01-26
Director/Board Member 62 17-01-02
Director/Board Member 67 14-10-31
More insiders
Date Price Change Volume
24-03-28 1.78 -0.56% 273,600
24-03-27 1.79 +1.70% 161,298
24-03-26 1.76 0.00% 302,463
24-03-25 1.76 -1.68% 277,924
24-03-22 1.79 -2.72% 324,851

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.78 USD
Average target price
6.625 USD
Spread / Average Target
+272.19%
Consensus
  1. Stock
  2. Equities
  3. Stock Corvus Pharmaceuticals, Inc. - Nasdaq